New targets for antithrombotic medications: seeking to decouple thrombosis from hemostasis
Open Access
- 13 December 2024
- journal article
- review article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (4) , 1146-1159
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist DevicesJACC: Heart Failure, 2024
- Reasons for Nonadherence to the Direct Oral Anticoagulant ApixabanJACC: Advances, 2023
- Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRDKidney International Reports, 2021
- Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart DiseaseJAMA Cardiology, 2021
- PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patientsCPT: Pharmacometrics & Systems Pharmacology, 2021
- Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear IndicationJAMA Internal Medicine, 2021
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee ArthroplastyJAMA, 2020
- Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse EventsJAMA Internal Medicine, 2019
- A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary EmbolismJACC: Cardiovascular Interventions, 2018
- Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial FibrillationArchives of internal medicine (1960), 2010